PolyPid Joins Consortium of EU's Seventh Framework Program to Develop Unique Treatment of Biofilm-Associated Infections
PolyPid, a developer of drug carriers, announced that the European Commission has approved a grant of €1 million to PolyPid, following its joining of a special pan-European consortium, the Biofilm Alliance (BALI), established to develop a unique treatment of biofilm-associated infections. The new treatment will be based on a combination of two technologies: Synthetic Antibacterial Antibiofilm Peptides (SAAP), and PolyPid's platform technology for the controlled and prolonged release of any Active Pharmaceutical Ingredient (API). The project, whose total budget is €4 million, is funded by the European Union’s Seventh Framework Program.
The project will explore antibacterial peptides entrapped with PolyPid technology and the controlled and sustained release of these peptides when used for coating of indwelling medical devices, to prevent and control biofilm-associated infections.
In addition to PolyPid, the BALI consortium comprises six companies and research organizations, including The Academic Medical Center of the University of Amsterdam, AO Research Institute, Leiden University Medical Center, AO Clinical Investigation and Documentation, Austrian Academy of Sciences, and Madam Therapeutics.
Other news from the department business & finance
